Biomarkers for psychiatry:The journey from fantasy to fact, a report of the 2013 CINP think tank by Scarr, Elizabeth et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1093/ijnp/pyv042
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Scarr, E., Millan, M. J., Bahn, S., Bertolino, A., Turck, C. W., Kapur, S., ... Dean, B. (2015). Biomarkers for
psychiatry: The journey from fantasy to fact, a report of the 2013 CINP think tank. International Journal of
Neuropsychopharmacology , 18(10). 10.1093/ijnp/pyv042
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
Received: January 8, 2015; Revised: March 18, 2015; Accepted: March 25, 2015
© The Author 2015. Published by Oxford University Press on behalf of CINP.
International Journal of Neuropsychopharmacology, 2015, 1–9
doi:10.1093/ijnp/pyv042
Review
1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, 
provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Review
Biomarkers for Psychiatry: The Journey from Fantasy 
to Fact, a Report of the 2013 CINP Think Tank
Elizabeth Scarr, PhD; Mark J. Millan, PhD; Sabine Bahn, MD, PhD, MRCPsych; 
Alessandro Bertolino, MD, PhD; Christoph W. Turck, PhD; Shitij Kapur, MBBS; 
PhD; Hans-Jürgen Möller, MD, PhD; Brian Dean, PhD
Department of Psychiatry, University of Melbourne, Victoria, Australia (Drs Scarr and Dean); The Molecular 
Psychiatry Laboratory, Florey Institute for Neuroscience and Mental Health, Victoria, Australia (Drs Scarr and 
Dean); Pole d’Innovation Thérapeutique en Neuropsychiatrie, Institut de Recherches Servier, Paris, France (Dr 
Millan); Cambridge Centre for Neuropsychiatric Research, University of Cambridge, UK (Dr Bahn); Pharma 
Research & Early Development, NORD, DTA, Hoffman - La Roche, Ltd., Basel, Switzerland (Dr Bertolino); School 
of Medicine, Basic Medical Sciences, Neuroscience and Sense Organs (DMBNOS), University of Bari, Italy (Dr 
Bertolino); Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, 
Germany (Dr Turck); Institute of Psychiatry, Kings College London, London, UK (Dr Kapur); Department of 
Psychiatry, Ludwig-Maximilians-University, Munich, Germany (Dr Möller)
Correspondence: Elizabeth Scarr, PhD, Psychiatric Neuropathology Laboratory, Department of Psychiatry, Kenneth Myer Building, University of 
Melbourne, VIC 3010 (elscarr@unimelb.edu.au)
Abstract
Background: A think tank sponsored by the Collegium Internationale Neuropsychopharmacologium (CINP) debated the status 
and prospects of biological markers for psychiatric disorders, focusing on schizophrenia and major depressive disorder.
Methods: Discussions covered markers defining and predicting specific disorders or domains of dysfunction, as well as 
predicting and monitoring medication efficacy. Deliberations included clinically useful and viable biomarkers, why suitable 
markers are not available, and the need for tightly-controlled sample collection.
Results: Different types of biomarkers, appropriate sensitivity, specificity, and broad-based exploitability were discussed. 
Whilst a number of candidates are in the discovery phases, all will require replication in larger, real-life cohorts. Clinical cost-
effectiveness also needs to be established.
Conclusions: Since a single measure is unlikely to suffice, multi-modal strategies look more promising, although they bring 
greater technical and implementation complexities. Identifying reproducible, robust biomarkers will probably require pre-
competitive consortia to provide the resources needed to identify, validate, and develop the relevant clinical tests.
Keywords: Animal studies, biomarkers, clinical samples, imaging, psychiatric disorders
Introduction
In 2013, the CINP Think Tank considered the potential of “clini-
cally useful biomarkers to define target populations,” with the 
concept that they would have the capacity to improve thera-
peutic outcomes or facilitate the development of novel, more 
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focused treatments. To date, there is only one commercial bio-
logical test for clinical use in psychiatric disorders, MDDScore, 
which augments standardized diagnostic interviews in iden-
tifying people with major depressive disorder (Bilello et  al., 
2013). This was the basis on which the CINP Think Tank brought 
together interested parties from industry and academia to 
debate how best to strategize and make practical plans to 
search for biomarkers for psychiatric disorders. The debate was 
wide-ranging, moving from why there are so few clinical tests 
in psychiatry to the types of biomarkers that would be most 
useful clinically, either for patient stratification or monitoring 
treatment efficacy. Rather than an exhaustive review of the lit-
erature, this report summarizes the Think Tank discussion of 
opportunities to be seized and challenges to be overcome in the 
discovery and validation of biomarkers for psychiatric disorders 
and their treatment.
Whilst there has been particular focus on diagnostic bio-
markers for psychiatric disorders, the reality is that this is only 
one example of a biomarker (see Figure 1). Other areas of med-
icine use markers in a number of ways. For example, human 
epidermal growth factor (Her2) and oestrogen and progester-
one receptors are used as markers for disease stratification in 
breast cancer (Vaz-Luis et al., 2013). Although no biomarker for 
Alzheimer’s disease has been universally recognized, decreased 
extracellular levels of beta amyloid in the brain are considered 
an early indicator of the risk of developing this neurodegenera-
tive disorder (Buchhave et  al., 2012), whilst the extent of car-
diac reperfusion following a cardiac arrest is used as a marker 
of prognosis (Neumar et  al., 2008). Markers can also be used 
to guide therapeutic decisions; it is recommended that people 
of Asian descent are tested for the human leukocyte antigen 
B*1502 (HLAB*1502) allele prior to commencing treatment with 
a range of anticonvulsants to avoid the risk of toxic epidermal 
necrolysis (US Food and Drug Administration, 2013). In psychi-
atry, lithium dosage varies considerably because the goal is to 
attain a specific plasma level which is known to be associated 
with a clinical effect (see Malhi et al., 2011), making plasma lith-
ium an effective theranostic. Given the range of potential uses, 
in order to identify suitable markers that will be clinically useful 
in psychiatry and determine how they will be used we must first 
decide what we want to achieve.
The discovery and development of biomarkers has greatly 
impacted the management and treatment of a number of medi-
cal conditions, such as diabetes and cancer. Conversely, the dis-
covery of a biomarker doesn’t invariably lead to improved clinical 
outcomes. Indeed, there are potential disadvantages and ethical 
issues associated with biomarkers that need to be considered 
as the field progresses. Unless there is a distinct benefit associ-
ated with using the biomarker, it will have little, if any, appeal 
to clinicians or patients. This is best illustrated by the fact that 
less than 20% of people with a family history of Huntington’s 
disease request testing to determine whether or not they will 
develop the disease (Meiser and Dunn, 2001). Since there is no 
therapeutic intervention available they perceive no benefit in 
knowing in advance that they will develop the disease. Indeed, a 
survey found that 15% of people at risk considered suicide to be 
an option should they develop symptoms (Mastromauro et al., 
1987), providing a powerful reason not to test people at risk of 
the disease. Conversely, a test with a clinical consequence can 
also have drawbacks. This is demonstrated by the use of pros-
tate-specific antigen (PSA) levels as a screen for prostate cancer; 
PSA can be elevated by benign events, thereby reducing the diag-
nostic specificity of the test. Approximately a quarter of the men 
with elevated PSA levels have prostate cancer and, of these, only 
a small number of cases would be fatal (Barry, 2001). Thus, the 
use of PSA levels alone would lead to the over-diagnosis of pros-
tate cancer, an increase in health care costs, and unnecessary 
anxiety for patients. Equally importantly, it has been reported 
that depression and suicide increases in men who are known to 
have an elevated PSA rather than purely in men who have pros-
tate cancer (Lehman, 2014). Thus, whilst the desired outcome 
in men with elevated PSA would be an evaluation for prostate 
cancer, the test itself is having detrimental outcomes in some 
individuals. This is an excellent demonstration that careful con-
sideration needs to be given to the use of biomarkers for psychi-
atric disorders if and when they become available.
Biomarkers in Psychiatry
Although clinical tests are well-established in other areas of 
medicine, their development in the field of psychiatry has been 
slow. There are a number of reasons associated with this, which 
have previously been dealt with in detail (Kapur et  al., 2012). 
Essentially, although the Diagnostic and Statistical Manual 
of Mental Disorders and the International Classification of 
Diseases provide common languages for clinical evaluations, 
neither provide information about the detailed (or individual) 
phenomenological presentation or their underlying causes. 
Furthermore, their diagnostic frameworks define syndromes 
(Tamminga, 2008), making it unlikely that any biomarker will 
align with these descriptors; rather, it is more likely that mark-
ers will be predictive of subsets of individuals that may dis-
play specific symptoms or symptom clusters. This in itself is 
not an undesirable outcome; most people visit a clinician to 
have symptoms treated rather than to obtain a diagnosis, but 
it requires a shift in our conceptualization of the role of bio-
markers in the “diagnosis” of psychiatric disorders. Rather than 
pursuing markers for diagnoses, it may be preferable to develop 
markers to stratify groups within the syndrome, which in turn 
may lead to more focused treatment options, possibly traversing 
nosological boundaries. This would be particularly important if 
we develop the capacity to identify people who will not respond 
well to standard first-line treatment options prior to treatment 
commencement. This approach is exemplified by the Research 
Domain Criteria (RDoC) established by the USA National Institute 
of Mental Health, which seeks to resolve the issues associated 
with mental illness independently of the current classification 
system used for diagnoses. This concept has the potential to 
provide ideal opportunities to develop biomarkers for specific 
behaviors, although to date none have been published.
Compounding the problem of trying to identify biomarkers 
for syndromes are issues with current study designs. Firstly, 
many studies assess a marker in a cohort with a uniform diag-
nosis and compare it to a control group (normally with no psy-
chiatric or neurological history). This is an example of extreme 
comparisons; whilst this approach is useful in a discovery cohort Figure 1. Potential clinical uses for biomarkers in psychiatry.
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at the start of a program to identify potential markers, many do 
not take the next step and assess the marker in a more clini-
cally-relevant cohort presenting with a variety of diagnoses. In 
addition, even these early phase studies do not control for issues 
around blood collection, such as fasting status, time of day (diur-
nal rhythms), and phase of oestrous cycle, which can be critical 
when measuring highly responsive markers such as cytokines 
(Dean, 2011b). These are some reasons why markers that appear 
to have great promise often fail to perform adequately in clinical 
testing, where they lack the refinement necessary to distinguish 
between psychiatric disorders. Furthermore, many studies have 
relatively small cohorts; whilst this is understandable given the 
issues associated with recruiting people with psychiatric condi-
tions, it means that most, if not all, are underpowered in statis-
tical terms unless the marker has a very high signal-to-noise 
ratio. The lack of statistical power is especially problematic 
when coupled with small effect sizes (Cumming, 2008), result-
ing in a field littered with discordant reports for the majority 
of markers. When these issues are combined with the problem 
of dealing with the heterogeneous population described by a 
syndrome, it is unsurprising that many follow-up studies fail to 
confirm the original finding. Indeed, often the original finding is 
not replicated but a similar finding is made. In psychology this 
is referred to as an approximate replication; whilst such studies 
do not reject the original finding, they do not support it either. 
The problem is that neither measure is going to be a useful bio-
marker. The question then is how to identify robust and reliable 
markers with a strong enough discriminative power to be clini-
cally relevant? The consensus of the Think Tank was that not 
only is it necessary to identify measures that can be replicated 
with a high degree of precision, but mechanisms to rapidly rep-
licate such findings need to be established.
Although they are not factors given much consideration 
when designing studies to test specific hypotheses, the reality 
is that clinical tests, irrespective of the underlying science, have 
to be both easy to implement and inexpensive. This latter point 
is illustrated by VeriPsych, a blood-based diagnostic aid to con-
firm the diagnosis of recent-onset schizophrenia and marketed 
by Rules Based Medicine (Schwarz et al., 2010). The blood-based 
assay determined levels of 51 analytes and distinguished people 
diagnosed with schizophrenia from people with no history of 
psychiatric disorders with a sensitivity of 85% and a specificity 
of 84%. VeriPsych was marketed in 2010 to aid with the initial 
diagnosis, where over 30% of people with bipolar disorder are 
misdiagnosed as having schizophrenia or a psychotic disor-
der (Gonzalez-Pinto et al., 1998). In 2011, Rules Based Medicine 
became Myriad RBM and in 2013 VeriPsych was withdrawn, pri-
marily due to cost, but also because of a desire for greater sen-
sitivity and specificity and a market drive for a test that would 
aid in making differential diagnoses. Thus, in addition to the 
enormous task and technological challenges of identifying bio-
markers, a number of other factors have to be taken into con-
sideration in the development and marketing of such tools for 
clinical deployment.
Biomarkers at the Discovery Phase
Despite the problems associated with the identification, devel-
opment, and marketing of biomarkers for psychiatric disorders, 
research is very active at the discovery level, using a range of 
modalities. One approach is the use of neuroimaging techniques 
to aid in diagnosis, drug response, and potentially drug develop-
ment in psychiatric disorders. Using machine-based learning in 
a small cohort, the pattern of gray matter volume changes from 
magnetic resonance images (MRIs) retrospectively predicted the 
transition of at-risk mental state participants with attenuated 
psychotic symptoms to psychosis with a sensitivity of 0.83 and 
a specificity of 0.80 (Koutsouleris et al., 2009). This was replicated 
in a second, small but independent clinical sample, with a sen-
sitivity of 0.81 and specificity of 0.87 (Koutsouleris et al., 2012a). 
Whilst the replication makes this approach promising, the 
authors only replicated the prediction accuracy within the same 
setting, leaving the complex question of how it is standardized 
across centers and imaging platforms. In addition, the time 
and costs associated with MRIs make it a difficult technique to 
market for routine tests, as required for biomarkers. Therefore, 
while MRIs are used clinically to identify contributing factors—
for example, silent clinical infarcts in late-onset depression (Wu 
et al., 2014)—researchers are engaged in generating robust, clin-
ically-replicated evidence for its utility as a biomarker.
Alternative complementary approaches include magnetic 
resonance spectroscopy to measure the response of combined 
levels of glutamate and glutamine (Glx) to ketamine infusion 
in healthy volunteers, as well as assessing differences between 
people with schizophrenia and control participants (see Poels 
et al., 2014 for a review). Using the Glx response to ketamine as 
a basis for developing drugs for schizophrenia has so far been 
unsuccessful; although the metabotropic glutamate 2/3 agonist 
Pomaglumetad methionil reversed the ketamine-evoked gluta-
mate release and showed positive phase II results, it failed to 
show a significant effect as an adjunct in phase III trials (Stauffer 
et  al., 2013). By contrast, high doses of D-cycloserine, which 
was introduced as a drug for tuberculosis, have been shown to 
be effective in some people with treatment-resistant depres-
sion when used as an adjunct to the current antidepressant 
(Heresco-Levy et al., 2013). People who had plasma glycine levels 
greater than 300 uM showed a better response to the adjunc-
tive therapy. Combined with the report that poor responses to 
selective serotonin reuptake inhibitors are associated with high 
plasma glycine levels (Ji et al., 2011), this raises the possibility 
that plasma glycine might be a marker for the stratification of 
patients with depression. However, further work is required to 
determine if this measure clearly delineates between respond-
ers and non-responders.
Another imaging modality is blood flow; a MRI study using 
gadolinium for contrast reported that high levels of basal cer-
ebral blood volume in the hippocampal CA1 subfield could be 
used to predict the transition from ultra-high risk to psycho-
sis (Schobel et  al., 2009). However, there was no clear separa-
tion between groups at the individual level, making this difficult 
to implement clinically. An alternative approach is the use of 
infrared scans to monitor blood flow in the forehead during a 
verbal fluency task. The rate of change in blood flow patterns 
was different between patients with schizophrenia compared 
to patients with major depressive disorder (Kinou et al., 2013). 
Following validation, this imaging approach may enable the dif-
ferential diagnosis between the two disorders, thereby rapidly 
initiating appropriate treatment for people with either disorder.
In addition to the neuroimaging strategies, a number of other 
clinical markers are being assessed for their diagnostic utility. 
With the current focus on the contribution of cognitive deficits 
to psychiatric disorders (Millan et al., 2012; Andreou and Bozikas, 
2013; Trivedi and Greer, 2014), it is not surprising that neurocog-
nitive data has been used to investigate whether specific deficits 
correlate with defined illness stages (Pukrop et al., 2006). To date, 
no individual test has achieved the level of sensitivity and speci-
ficity required for a diagnostic marker. However, using patterns 
of neurocognitive performance across premorbid verbal IQ, 
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processing speed, working memory, verbal and visual memory, 
and executive function has been reported to distinguish healthy 
controls from people with an at-risk mental state- with a sensi-
tivity of 0.96 and a specificity of 0.80 (Koutsouleris et al., 2012b). 
The same neurocognitive performance data also retrospectively 
identified people with at-risk mental states who transitioned to 
psychosis from those who did not with a sensitivity of 0.80 and 
a specificity of 0.75 (Koutsouleris et al., 2012b). As discussed for 
the gray matter volume analysis, these outcomes are not likely 
to be accurate enough to be used as diagnostic markers in their 
own right, but their predictive value might be enhanced by com-
bining them with other markers, in line with recent exploration 
of multimodal markers and the risk of transition (Fusar-Poli 
et al., 2013).
Within psychiatric disorders there is a relatively high degree 
of heritability: 0.81 for schizophrenia, 0.75 for bipolar disorder, 
and 0.37 for major depressive disorder (Sullivan et  al., 2012). 
Thus, one approach to biomarker discovery is to harness the 
heritability of these disorders and look for genetic markers. 
Following reports of a partial overlap in the genetic vulnerability 
between psychiatric disorders (The International Schizophrenia 
Consortium, 2009; Cross-Disorder Group of the Psychiatric 
Genomics Consortium, 2013a), there has been a drive to iden-
tify genetic markers for phenotypes rather than continuing 
with the historic diagnostic labels. Using this approach, a role 
for calcium channel signaling has been identified in autism 
spectrum disorder, attention deficit-hyperactivity disorder, 
bipolar disorder, major depressive disorder, and schizophrenia 
(Cross-Disorder Group of the Psychiatric Genomics Consortium, 
2013b). It remains to be determined whether these findings 
translate into either a better understanding of the causes of 
these disorders or novel drug targets, which might be of particu-
lar use during the pre-clinical phase of adult-onset disorders, 
allowing a non-specific intervention that trans-nosologically 
impedes conversion. The logical progression of these findings 
has resulted in studies to determine whether particular clinical 
features are associated with genetic markers. One of the first 
studies to assess this reported a significant impact of the cat-
echol-O-methyl transferase (COMT) functional polymorphism 
[rs4680; Val(108/158)Met] with working memory as assessed by 
the N-back task (Bertolino et al., 2004). The methionine substitu-
tion, which confers lower activity of this enzyme responsible for 
the catabolism of dopamine, was associated with a better per-
formance on the task. Furthermore, people with this allele also 
showed greater improvements in working memory and nega-
tive symptoms following treatment with olanzapine, raising the 
possibility it might serve as an indicator for treatment respon-
sivity. Recent findings also link a functional polymorphism 
(rs6314) in the serotonin (5-hydroxytryptamine) 2A receptor to 
performance on cognitive tasks and response to olanzapine 
(Blasi et al., 2013). In this instance, the T allele was associated 
with lower levels of receptor expression, poorer performance on 
the trail making test, the prescription of higher doses, and an 
attenuated response to olanzapine. Together, the associations of 
these polymorphisms suggest that batteries of polymorphisms, 
rather than individual ones, might be required to understand 
the nuances of interactions between behavior, cortical circuitry, 
and, ultimately, treatment response across psychiatric disor-
ders. This posit is in accordance with current notions of epista-
sis and the need for pathway analyses when examining patterns 
of genetic risk (Sullivan et al., 2012). The complexity of the pic-
ture is underlined by the fact that the COMT Met  allele was 
not associated with performance on a working memory task 
in people with major depressive disorder (Opmeer et al., 2013); 
however, it should be noted that the task used was the Tower of 
London, not the N-back task. Given the levels of heritability for 
the psychiatric disorders, it is evident that genes are not the sole 
contributors to susceptibility for the disorders. With our increas-
ing understanding of the role played by epigenetics in modify-
ing gene expression as a response to environmental events, 
the impact of these dynamic mechanisms on the expression 
levels of genes has increasingly been examined (Millan, 2013). 
Investigations into the epigenetics of COMT have revealed that 
methylation of the valine at the rs4680 site in response to stress 
is associated with reduced enzyme expression and has a mod-
erate, positive association with performance on the N-back task 
(Ursini et al., 2011). Thus, both genetic and epigenetic markers 
across heritable phenotypes are an active area of research. This 
is attested to by recent publications regarding polygenic risk 
scores in psychiatry and frontal brain activation (Whalley et al., 
2015), schizophrenia and working memory (Kauppi et al., 2014), 
and stressful life events and depressive symptoms (Musliner 
et al., 2014). However, like other markers discussed in this report, 
they need to be properly validated.
Advances in high-throughput techniques are being har-
nessed to identify changes in the “omics” associated with psy-
chiatric disorders. These approaches have two goals: firstly to 
understand more about the pathogenesis of the disorder and 
secondarily to detect markers that will help in the identification 
and treatment strategies for people with the disorder. It is now 
established that the cytokine system is disrupted in psychiat-
ric disorders (Dean, 2011b), including major depressive disorder 
(Stelzhammer et al., 2014)—particularly the pro-inflammatory 
members of the family (Xu et  al., 2012)—schizophrenia (de 
Witte et  al., 2014; Fillman et  al., 2013), and bipolar disorder 
(Brambilla et  al., 2014; Bauer et  al., 2014). Likewise, oxidative 
stress markers have been reported in major depressive disor-
der (Stelzhammer et al., 2014), schizophrenia (Liu et al., 2014), 
and bipolar disorder (Brown et al., 2014). Given the widespread 
changes reported in these factors, the potential use of specific 
members of these families as biomarkers remains to be deter-
mined, based on their specificity for the event in question. An 
additional advantage of these large-scale studies is that reports 
of markers that identify subgroups within the diagnostic cat-
egory are gradually emerging. The most progress in this aspect 
has been made in schizophrenia, where subgroups have been 
identified on the basis of binding to the muscarinic M1 recep-
tor (Scarr et al., 2009), levels of cytokines (Fillman et al., 2013; 
Schwarz et  al., 2014), growth factors and hormonal pathways 
(Schwarz et al., 2014), and patterns of polymorphisms (Arnedo 
et al., 2015). Until the division of schizophrenia into biological 
subgroups has a clinical significance or outcome, the identifica-
tion of these and similar markers will be of academic interest 
only. However, if therapies are developed that are more suitable 
for a subgroup or a specific subgroup is associated with a par-
ticular prognosis, then the ability to identify that group will be 
of great clinical interest.
Predicting and Tracking Medication Efficacy
Finally, the quest for biomarkers that will predict treatment 
response is attracting attention from clinicians, regulators, and 
pharmaceutical companies. However, research is still at an early 
phase so there are relatively few studies available. In major 
depressive disorder, high levels of histone deacetylase 5 prior to 
treatment initiation appear to be a robust marker for treatment 
response (Iga et al., 2007; Hobara et al., 2010; Belzeaux et al., 2010). 
Levels of cyclic-adenosine monophosphate (cAMP) response 
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element binding protein 1 (Iga et al., 2007), histone deacetylase 
2 (Hobara et  al., 2010), serotonergic markers (Belzeaux et  al., 
2010), a panel of four gene expression profiles (Belzeaux et  al., 
2012), and interferon regulatory factor 7 (Mamdani et  al., 2011) 
have variously been reported to change following treatment with 
antidepressants. Within schizophrenia, a small study reported 
that clinical improvement following treatment with unspecified 
second-generation antipsychotics was associated with a return 
to control levels of peripheral Dishevelled-Associated Activator 
Of Morphogenesis (Kuzman et al., 2009). Another study reported 
that mRNA levels of neuropilin and tolloid-like (NETO) and proto-
oncogene AF4/Fragile X E mental retardation syndrome (AF4/
FMR2) Family Member 3 (AFF3) were significantly altered after 
3 weeks of treatment in responders to olanzapine or risperi-
done compared to non-responders (Mamdani et  al., 2013). For 
bipolar disorder, there are no reports of clear indicators of treat-
ment response to antipsychotic medications. However, vascular 
endothelial growth factor A was reported to be decreased follow-
ing treatment with lithium in small groups of healthy individuals 
and patients with bipolar disorder (Kikuchi et al., 2011). Whilst 
this has potential for use as a marker of medication compli-
ance, it provides no clue as to treatment response. By contrast, 
an investigation of gene expression profiles between depressed 
people with bipolar disorder who did (n = 10; 50+% reduction in 
initial score on the Hamilton depression rating scale) and did not 
(n = 10) respond to lithium reported that people who responded 
had an increased ratio of anti-apoptotic to pro-apoptotic B-cell 
lymphoma 2 (Bcl2) family members, whilst the converse was true 
for those who did not respond (Lowthert et al., 2012). Whether 
the same expression profiles will predict response of the manic 
phase to treatment remains to be determined. Whilst all these 
findings are of potential interest, for such markers to be truly 
useful they need to be prospectively, as well as retrospectively, 
accurate. In addition, many of these studies have been conducted 
in small cohorts. As previously discussed, under-powered sample 
sizes are a major contributor to the non-replication and pseudo-
replication that dog this area of research. Thus follow-up studies 
in larger, independent cohorts are required to advance these find-
ings beyond the discovery phase.
One tactic to identify markers for treatment stratification is 
to employ a “bottom up” scheme, identifying potential markers 
in animal models with relevant phenotypes and then assessing 
their validity in patient samples. One example of this approach 
is a mouse which overexpresses the SH3 and Multiple Ankyrin 
Repeat Domains 3 (SHANK3) gene (Han et al., 2013). This mouse 
was developed because of the association of loss and/or over-
expression of this gene with several neuropsychiatric disorders. 
Duplications spanning SHANK3 result in its overexpression; 
transgenic animals exhibit hyperactivity, reduced pre-pulse 
inhibition, hyperphagia, and abnormal circadian rhythms, pro-
viding face validity for bipolar disorder. The hyperactivity and 
abnormal pre-pulse inhibition were reversed by valproate but 
not lithium. Thus, SHANK3 genotyping might be useful in identi-
fying patients with bipolar disorder who will not respond well to 
lithium prior to treatment initiation. Examining the proteomes 
of mice that exhibited high and low scores on a test associ-
ated with anxiety led to the identification of single nucleotide 
polymorphisms in enolase phosphatase, resulting in a lower 
activity of the enzyme which forms part of the methionine sal-
vage pathway (Ditzen et  al., 2010). A  product of this pathway, 
S-adenosyl-L-methionine, was tested as an antidepressant with 
varying outcomes; a meta-analysis determined that it has an 
efficacy similar to that of tricyclic antidepressants (Bressa, 1994). 
The preclinical studies suggest that genotyping patients prior to 
treatment might improve the clinical utility of this compound. 
The ability to clinically identify subgroups within syndromes 
that will respond preferentially to different types of treatment 
modalities and reliably predict drug effectiveness in individual 
patients has the potential to dramatically change treatment and 
drug development for psychiatric disorders from the current 
“one size fits all” approach to a much more personalized treat-
ment plan.
How do We Move the Concept of 
Biomarkers Forward?
As can be seen from the preceding efforts to identify various 
biomarkers, the discovery phase of biomarker development is 
very active. There are two fundamental answers to the question 
of how we can expedite the development of biomarkers from 
discovery through validation and marketing to the clinic. Firstly, 
it is critical that the measure is rigorous, precise, and repro-
ducible. For example; working memory is often used as a task 
for functional neuroimaging, but there are different forms of 
working memory: spatial, visual, and verbal modalities are all 
widely used. However, do they measure the same thing? How 
do scores on the N-back test relate to scores on the trail mak-
ing test? Thus, to avoid generating approximate replications, if a 
particular neuropsychological tool has potential as a biomarker, 
the validation and eventual clinical use of it must employ the 
original protocol to retain the unique specificity and sensitiv-
ity of the test. The same principles also apply to biochemical 
markers, as peripheral levels of many gene products and metab-
olites will vary throughout the day and, furthermore, some may 
be influenced by external factors. For any biochemical entity to 
be assessed, it is vital that the physiological constraints in the 
general population are known so that collecting and processing 
samples can be optimized. It is then vital that a standardized 
protocol encompassing sample collection, storage, processing, 
and marker measurement is developed and strictly adhered to 
in order to retain the integrity of the test. Ideally, any workflow, 
from measuring the test to producing an answer, will have as 
few nodes as possible to keep variation to a minimum. In addi-
tion, as previously suggested (Dean, 2011a), it is critical for 
researchers in the field to develop networks to expedite the vali-
dation of potential biomarkers so that validated biomarkers can 
rapidly be moved into the clinic.
Secondly, the search, validation, and subsequent marketing 
of biomarkers will require funding in excess of that generally 
available from the current funding sources. The process will also 
need to bring people with very divergent expertise together in 
a collaborative atmosphere. Ideally there would be clinical and 
basic researchers, ready access to well-curated samples, coor-
dination of the research effort, knowledge of the requirements 
of diagnostic kits, and eventually expertise in marketing the 
product. The best model currently available for this type of ven-
ture is a pre-competitive consortium, of which Novel Methods 
leading to New Medications in Depression and Schizophrenia 
(NEWMEDS) (Tansey et al., 2012) is an example. NEWMEDS was 
established by the Innovative Medicines Initiative, which is a 
public/private undertaking between the European Union and 
the European Federation of Pharmaceutical Industries and 
Associations to find new methods of developing drugs for schiz-
ophrenia and depression (http://www.newmeds-europe.com/
index.php). The consortium has 19 partners from 12 countries, 
including 10 pharmaceutical companies, seven academic insti-
tutions, and two small- and medium-sized enterprises, with 
management being handled by a third such enterprise. As part 
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of their research agenda, the consortium has determined that 
genotyping cannot be used to predict responses to antidepres-
sant drugs (Tansey et al., 2012) and assessed factors that predict 
antipsychotic drug response (Rabinowitz et al., 2014). These and 
other outcomes demonstrate that it is possible for a large dis-
parate collection of interests to work collaboratively to achieve 
a common goal. A  pre-competitive initiative, the P1vital CNS 
Experimental Medicine Consortium, has recently been formed 
with the express intention of “validating the next generation of 
biomarkers in schizophrenia.” This consortium has five phar-
maceutical companies and collaborates with five academic 
institutions. To date, they have assessed the effects of atypi-
cal antipsychotic drugs and nicotine on four biomarker tasks 
in people who were high schizotypes, as well as performance 
and brain activation of high schizotypes on virtual mazes (see 
Dourish and Dawson, 2014). It remains to be determined how 
well these markers perform in real-life clinical populations. 
Since this initiative closely matches one of the suggestions aris-
ing from the 2013 Think Tank, it will be interesting to see how 
it performs.
Summary
During the two days of intense discussion that constituted the 
2013 Think Tank, a number of significant points were made and 
endorsed by the attendees. The following are key messages 
resulting from this meeting:
•	 There is great potential for biomarkers within psychiatry. 
Potential uses include diagnosis, prognosis (risk), predic-
tion and evaluation of responses to treatment, avoidance 
of adverse events, and identification of specific subgroups 
within diagnostic syndromes.
•	 In order to identify useful biomarkers, it is necessary to rec-
ognize that genes and their products do not code for symp-
toms or disorders, therefore we should not expect them to be 
specific to diagnoses. Furthermore, epigenetic changes may 
overwrite the genetic blueprint.
•	 Predictors need to have accuracy at the individual level in 
real life, not just statistically significant differences between 
group means in experimental studies.
•	 It is vital to standardize measurements and tests across 
groups or centers around the world to ensure the reproduc-
ibility, reliability, and robustness of tests.
•	 Since the “all or none” effect seen in specific types of cancer 
is unlikely to occur in psychiatric disorders, it will be neces-
sary to develop normative data for the markers.
•	 We need simple, cost-effective readouts if biomarkers are to 
be used on a broad-based scale for risk estimation and pre-
dicting responses to treatment by specialists or in general 
practice.
•	 Single biomarkers may not be enough; for example, in pre-
dicting the risk of psychosis or depression, multi-modal 
approaches may be more reliable. There is a diversity of 
potential readouts that can be combined, including biochem-
ical, cognitive, electrophysiological, genetic, and neuroimag-
ing tests.
•	 Longitudinal studies, assessing the expression of a battery of 
markers over a significant period of time, might prove to be 
more discriminating than cross-sectional studies.
•	 A large number of potential markers are under investiga-
tion at the discovery stage. In order to move these forward, 
replication studies in much larger, independent cohorts are 
essential.
•	 There is a need for pre-competitive partnerships, possibly 
academic, industry, or government, to successfully iden-
tify and validate markers so that reliable clinical tests can 
be developed. Including patients and regulators in discus-
sions would assist in setting targets since market forces and 
consumer needs do not necessarily align with clinical or 
research questions.
Despite formidable challenges, much progress has been made 
and will continue to be made towards the clinically-important 
goal of developing valid, reliable, and broadly-usable biomarkers 
for psychiatric disorders and their treatment. However, we have 
to be realistic about the time it takes to identify, validate, and 
market biological tests. It might be that a test may not be per-
fect initially, with its true value and application only emerging 
once it is in wider use in the clinic. The question to be answered 
is how good a test has to be to get the chance to make it into 
the clinic. In essence, addressing that question will require the 
identification of universally accepted parameters that biomark-
ers would be useful for. Once these have been established, all 
aspects of sample collection, processing, and storage, whether 
they are biological material, or physiological readouts, need to 
be standardized. Potential markers will require rigorous evalu-
ation of their sensitivity, specificity, predictive value, and like-
lihood ratio before being tested in a larger validation cohort 
that reflects a normal clinical population. Normative data will 
also need to be generated for these markers. If successful, the 
significant final steps will be to develop a cost-effective, easily 
implementable diagnostic tool that does not require access to 
highly specialized equipment that would restrict its use. CINP 
has already supported this process by sponsoring a forum, in 
the form of the Think Tanks, for the unencumbered exchange 
of ideas necessary for such an ambitious program to be imple-
mented. Programs that promote cross-discipline collabora-
tions, such as RDoC, and the specialized research consortia 
that already exist can also make significant contributions to the 
development and implementation of such a scheme.
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